Hester Biosciences Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2018. The company net sales have gone up by 32% as compared to the equivalent first quarter of last to last year the company recorded sales of INR 382.6 million as against INR 290.4 million. The reason for this topline growth is mainly attributed to the expanded capacity and also shifting the company focuses on high value products. Talking about the net profit the profit of the company has improved the company's EBITDA as well as the net profit and the attributes for this are again that the company has improved the company's cost of goods sold there has been higher efficiencies in the company's production that have been incorporated as well as better inventory management. Net profit is achieved at 25.31% of total sales for first quarter of fiscal year 2019 as against 21.18% of sales in first quarter of fiscal year 2018. The company has invested INR 13.2 million in capex during the first quarter of fiscal year 2019 as against INR 43.0 million in first quarter of fiscal year 2018. ROE stands at 24.87% as against 19.55% for the quarter. Non-annualized EPS for first quarter fiscal year 2019 is at INR 11.38 per share as against INR 7.23 per share in first quarter of fiscal year 2018. Consolidated debts are INR 517.4 million in the fiscal first quarter of 2019 as against INR 600.2 million for fiscal year 2018. Total Revenue was INR 390.33 million compared to INR 295.94 million a year ago. Profit before tax was INR 134.04 million compared to INR 94.41 million a year ago. Profit for the period was INR 96.84 million compared to INR 61.76 million a year ago.

For the current fiscal year 2019, the company expects to maintain a growth in sales at least what the company has shown and on the profit side the minimum that the company will have is what the company has registered in this quarter.